GUTS Stock Overview
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Fractyl Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.34 |
| 52 Week High | US$14.50 |
| 52 Week Low | US$5.75 |
| Beta | 0 |
| 1 Month Change | -13.86% |
| 3 Month Change | -39.04% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| GUTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -9.2% | -0.2% | 0.6% |
| 1Y | n/a | -1.1% | 23.9% |
Return vs Industry: Insufficient data to determine how GUTS performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how GUTS performed against the US Market.
Price Volatility
| GUTS volatility | |
|---|---|
| GUTS Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GUTS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GUTS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 102 | Harith Rajagopalan | fractyl.com |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. Fundamentals Summary
| GUTS fundamental statistics | |
|---|---|
| Market cap | US$303.55m |
| Earnings (TTM) | -US$94.27m |
| Revenue (TTM) | US$120.00k |
2,530x
P/S Ratio-3.2x
P/E RatioIs GUTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUTS income statement (TTM) | |
|---|---|
| Revenue | US$120.00k |
| Cost of Revenue | US$77.00k |
| Gross Profit | US$43.00k |
| Other Expenses | US$94.31m |
| Earnings | -US$94.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 35.83% |
| Net Profit Margin | -78,559.17% |
| Debt/Equity Ratio | -146.2% |
How did GUTS perform over the long term?
See historical performance and comparison